How to Buy Taysha Gene Therapies Stock
Taysha Gene Therapies Inc
Taysha Gene Therapies, Inc. , a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system.
Taysha Gene Therapies stock last closed at $1.77, up 6.63% from the previous day, and has decreased 42.16% in one year. It has overperformed other stocks in the Biotechnology industry by 0.39 percentage points. Taysha Gene Therapies stock is currently +48.74% from its 52-week low of $1.19, and -59.03% from its 52-week high of $4.32.
As of Mar 25, 2025, there are 205M shares of TSHA outstanding. The market capitalization of TSHA is $362.85M. In the last 24 hours, 1.67M TSHA shares were traded.
How to Buy Taysha Gene Therapies Stock
Not sure how to invest in Taysha Gene Therapies stock? Here's how.
- Choose where to buy Taysha Gene Therapies stock: You need to decide on an online brokerage, but don't worry - we've researched dozens of online stock brokerages and apps to help you decide where to buy Taysha Gene Therapies stock.
- Create your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
- Deposit funds into your brokerage account: Pick your payment method and add your information.
- Analyze Taysha Gene Therapies stock: The Taysha Gene Therapies ticker symbol is TSHA. Is Taysha Gene Therapies stock a good investment? Should you buy shares of TSHA? How do TSHA's underlying business fundamentals look? Do top analysts think Taysha Gene Therapies is a good buy? Why has TSHA's stock price moved recently? (Hint: Our stock market analysis tools can help you understand if TSHA is a good stock to buy).
- Make your TSHA purchase: Decide if you will purchase TSHA shares at the current market price or use a limit order to purchase TSHA shares at a specific price.
- Keep an eye on your TSHA investment: Create a watchlist to keep tabs on your investment in Taysha Gene Therapies shares.
Step 1: Choose where to buy Taysha Gene Therapies stock
You need an online brokerage account to access the NASDAQ market and buy TSHA stock.
Our favorite brokerage: eToro
Based on our experience, eToro is the best stock brokerage. eToro gives you:
- You can invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still buy the stock.
- Access to global markets: From Technology to Healthcare, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading exchanges.
- Social investing: eToro offers a community with more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your share purchase by creating an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Create your brokerage account
Now that you've selected the right brokerage, the next step is to fill out some personal details so you are able to buy TSHA stock today.
How to Set Up a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal data to create your new trading account.
- Submit your data by clicking the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your brokerage account
Now that you have opened your account on the stock trading app, your next step is to transfer the money for your investment:
Watch this video walkthrough to see the process of transferring funds into your new brokerage account.
Step 4: Analyze Taysha Gene Therapies stock
Once you have selected the best place to buy Taysha Gene Therapies stock, it's critical to analyze their stock before you invest, so you can understand the risk as well as the upside.
Overview of key TSHA info
TSHA Fundamentals
WallStreetZen was designed to help everyday investors do better fundamental analysis in minutes instead of hours.
You can view all of the due diligence checks on TSHA's stock page.
Is TSHA stock undervalued or overvalued?
You can use many financial metrics, analyses, models, and charts to gauge TSHA's intrinsic value.
Using relative valuations ratios:
- TSHA could be overvalued based on its P/B ratio of 5.07x, relative to Biotechnology industry P/B ratio of 4.62x
You can access additional valuation analysis on TSHA's stock here.
TSHA Financial Summary
Passed Health Checks:
- There are more short-term assets than short-term liabilities on the TSHA balance sheet.
- TSHA has $141.64M in cash and short term investments. This is sufficient to cover its annual cash burn of $81.60M.
- Total TSHA debt is lower than 5 years ago, relative to shareholder equity.
- There are more short-term assets than long-term liabilities on the TSHA balance sheet.
- TSHA has cash burn of 81599000. It has sufficient cash and short-term investments to cover this for at least one year.
Failed Health Checks:
- TSHA has a relatively high debt to equity ratio of 1.24.
- TSHA profit margin has gone down from -722.1% to -1,071.6% in the past year.
Do Wall Street analysts think it's a good time to buy Taysha Gene Therapies stock
Out of 5 Equities analysts who track TSHA, the consensus analyst rating on Taysha Gene Therapies is a Strong Buy
Please note that analyst forecasts are not recommendations, nor are they financial advice.
You can dig deeper into what analysts are saying on the Taysha Gene Therapies stock forecast page.
TSHA Technicals
How is TSHA performing as a company?
Last year, TSHA revenue was $8.33M. In the past 2 year, TSHA's revenue has grown by 82.5% per year. This was faster than the Biotechnology industry average of 46.11%.
Find out more about TSHA's earnings and revenue performance here.
Who is buying/selling TSHA?
Over the past 12 months, executives and large shareholders at TSHA have bought more shares than they have sold.
Kamran Alam, CHIEF FINANCIAL OFFICER of TSHA, was the latest TSHA insider to sell. They sold $50,434.67 worth of TSHA stock on Mar 11, 2025.
Dig into more about who owns TSHA stock here.
Does TSHA stock generate passive income?
No, Taysha Gene Therapies doesn't provide an income stream by paying out dividends.
Get analysis from other traders
One of the reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to see what other community members have to say.
Step 5: Make your TSHA purchase
There are two primary order types:
- Market order: A market order is an order to buy or sell a stock at the best possible price.
Market orders are usually the easiest way to buy. - Limit order: A limit order allows you to buy or sell a security at a specific price (or better).
If you want to be certain you're buying or selling at a particular price limit, use a limit order.
Click the Open Trade button and eToro will place the order.
If you require more assistance investing in stocks on eToro, watch the how to video below:
Step 6: Keep an eye on your TSHA investment
Now that you own some TSHA stock, you'll want to keep up with your shares.
Put TSHA on a watchlist to get notified of important updates regarding your TSHA stock.
TSHA Feed
How to Buy Stock in Taysha Gene Therapies
To reiterate, here are the 6 steps you need to take to buy Taysha Gene Therapies stock right now:
- Choose where to buy Taysha Gene Therapies stock
- Create your brokerage account
- Deposit funds into your brokerage account
- Analyze Taysha Gene Therapies stock
- Make your TSHA purchase
- Keep an eye on your TSHA investment
If you require a brokerage, eToro is our favorite venue.
Get Started with eToro TodayIf you would like to track your new investment in Taysha Gene Therapies, click below.
Trending "How To" Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.